Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assess and Compare the Efficacy and Safety of FOLFOX Combined With Cetuximab Versus FOLFOXIRI Combined With Bevacizumab When Both Used in Combination With QL1706 for First-line Treatment of Metastatic Colorectal Cancer With Left-sided Primary Tumors.

NCT07070713 is registered in ClinicalTrials.gov with Fujian Cancer Hospital as lead sponsor.

NCT NCT07070713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07070713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assess and Compare the Efficacy and Safety of FOLFOX Combined With Cetuximab Versus FOLFOXIRI Combined With Bevacizumab When Both Used in Combination With QL1706 for First-line Treatment of Metastatic Colorectal Cancer With Left-sided Primary Tumors.
Lead sponsor
Fujian Cancer Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 30, 2025
Completion date
August 30, 2028
Enrollment
44 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immunotherapy, metastatic colorectal cancer with left-sided primary tumor